Zelira Therapeutics Completes Last Patient Dosing in Clinical Trial

  • Dec 17, 2019 AEDT
  • Team Kalkine

Zelira Therapeutics Limited (ASX: ZLD) has announced that last patient has completed dosing in its pioneering medicinal cannabis trial cannabis for insomnia. The company expects to report half-year results by February 2020.

  • It is said that no adverse events have been reported to date.
  • Centre for Sleep Science – University of Western Australia, has led the clinical trial.
  • It is evaluating the safety and efficacy of drugs containing THC and CBD for chronic insomnia.

By 1:35 PM AEDT, ZLD was trading at $0.057, up by 3.63% from the previous close.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK